Nordic Nanovector til himmels på melding
Nordic Nanovector flyr til topps på vinnerlisten på børsmelding.
Nordic Nanovector stiger 15 prosent til 28,40 kroner etter publisering av en børsmelding med den klingende tittelen:«Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity».Her finner du originalmeldingen:«ePoster to be presented at the 21st Congress of the European Hematology Association (9-12 June)Oslo, Norway, 10 June 2016Nordic Nanovector ASA (OSE: NANO) announces that pharmacokinetic analyses of a clinical study in patients with non-Hodgkin lymphoma (NHL) demonstrate that pre-dosing with the anti-CD37 antibody HH1, prior to injection with Betalutin® (177Lu-HH1) significantly increases the pharmacokinetic exposure of NHL tumour cells to Betalutin® (p < 0.001) while protecting against haematological side effects.The study, part of the ongoing Lymrit 37-01 Phase 1/2 trial of Betalutin® in NHL, evaluated 13 NHL patients who received different doses of Betalutin® either with or without HH1 pre-dosing. The analysis will be presented in an ePoster at the 21st Congress of the European Hematology Association (Copenhagen, Denmark, 9-12 June) by Dr Arne Kolstad, a senior consultant in medical oncology and radiotherapy at Oslo University Hospital, Radiumhospitalet and a member of Nordic Nanovector's Scientific Advisory Board. The poster is available here EHA 2016 (http://www.nordicnanovector.com/uploads/images/Financial -Reports/Poster%20EHA%202016%20-%20Copenhagen,%20DK.pdf)and at www.nordicnanovector.com in the section: Product Info/Scientific Posters.Jostein Dahle, Nordic Nanovector CSO, commented: "The results presented in this poster continue to support our hypothesis that pre-dosing provides a protective effect on healthy tissues when used prior to Betalutin® treatment." The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin® and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the Phase 2 PARADIGME study, which is expected to start in 2H 2017.»